Translation, Cross-Cultural Adaptation, Reliability and Construct Validity of the FACT- EGFRI-18 Quality of Life Instrument from English into Portuguese
DOI:
https://doi.org/10.32635/2176-9745.RBC.2024v70n3.4672Keywords:
ErbB Receptors, Translating, Reproducibility of Results, Surveys and Questionnaires, Quality of LifeAbstract
Introduction: Adverse epidermal growth factor receptor (EGFR) dermatological events affect many patients and can impair the patient’s quality of life (QoL), leading to dose reduction or discontinuation of therapy. Objective: To carry out the translation, cross-cultural adaptation, reliability and validity of the Functional Evaluation of Cancer Therapy - Epidermal Growth Factor Receptor Inhibitor 18 (FACT-EGFRI-18) to be utilized in Portuguese. Method: Study to evaluate the cross-cultural adaptation, reliability and construct validation of the FACT-EGFRI-18 translated into Portuguese. To evaluate cross-cultural adaptation, semantic analysis was performed by ten patients and content analysis by experts. Reliability was assessed by internal consistency analysis using Cronbach’s alpha coefficient. Construct validity was determined by the correlation between the translated FACT-EGFRI-18 and the Dermatology Life Quality Index (DLQI) answered by 30 participants with cancer undergoing treatment with EGFR. A descriptive analysis of the study population was performed and Cronbach’s alpha coefficient was calculated to determine the internal consistency of the Portuguese version of the FACTEGFRI- 18 and Pearson’s demonstration coefficient was applied to determine the transparency between the questionnaires. ANOVA test was performed to compare the mean FACT-EGFRI-18 score according to demographic variables. Results: The semantic evaluation showed that all the participants understood the items of the translated questionnaire, which revealed strong internal consistency (Cronbach’s alpha = 0.89) and validity (Pearson's correlation = 0.66). Conclusion: The FACT-EGFRI-18 was easily understood by the patients and the results support its reliability and validity.
Downloads
References
Chiang TY, Hsu HC, Chern YJ, et al. Skin toxicity as a predictor of survival in metastatic colorectal cancer patients treated with anti-egfr: fact or fallacy? Cancers (Basel). 2023;15(6):1663. doi: https://doi.org/10.3390/cancers15061663 DOI: https://doi.org/10.3390/cancers15061663
Lacouture ME, Mitchell EP, Piperdi B, et al. Skin Toxicity Evaluation Protocol With Panitumumab (STEPP), a phase ii, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J ClinOncol. 2010;28:1351-7. DOI: https://doi.org/10.1200/JCO.2008.21.7828
Saito Y, Uchiyama K, Takekuma Y, et al. Risk factor analysis for anti-epidermal growth factor receptor monoclonal antibody-induced skin toxicities in real-world metastatic colorectal cancer treatment. Support Care Cancer. 2023;31(8):504. doi: https://doi.org/10.1007/s00520-023-07973-3 DOI: https://doi.org/10.1007/s00520-023-07973-3
Hu JC, Sadeghi P, Pinter-Brown LC, et al. Cutaneous side effects of epidermal growth fator receptor inhibitors: clinical presentation, pathogenesis, and management. J Am Acad Dermatol. 2007;56:317-26. DOI: https://doi.org/10.1016/j.jaad.2006.09.005
Saito Y, Uchiyama K, Takekuma Y, et al. Evaluation of the additional prophylactic effect of topical steroid ointment to systemic minocycline against anti-epidermal growth factor antibody-induced skin toxicities in metastatic colorectal cancer treatment. Support Care Cancer. 2023;32(1):8. doi: https://doi.org/10.1007/s00520-023-08195-3 DOI: https://doi.org/10.1007/s00520-023-08195-3
Deslandres M, Sibaud V, Chevreau C, et al. Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors. Ann Dermatol Venereol. 2008; (esp1):16-24. doi: https://doi.org/10.1016/s0151-9638(08)70093-0 DOI: https://doi.org/10.1016/S0151-9638(08)70093-0
Osio A, Mateus C, Soria JC, et al. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors. Br J Dermatol. 2009;161:515-21. DOI: https://doi.org/10.1111/j.1365-2133.2009.09214.x
Belum VR, Cercek A, Sanz-Motilva V, et al. Dermatologic adverse events to targeted therapies in lower GI cancers: clinical presentation and management. Curr Treat Options Oncol. 2013;14:389-404. DOI: https://doi.org/10.1007/s11864-013-0254-4
Sibaud V, Robert C. Pigmentary disorders induced by anticancer agents. Part II: targeted therapies. Ann Dermatol Venereol. 2013;140(4):266-73. doi: https://doi.org/10.1016/j.annder.2013.01.442 DOI: https://doi.org/10.1016/j.annder.2013.01.442
Ruiz JN, Belum VR, Boers-Doets CB, et al. Nasal vestibulitis due to targeted therapies in cancer patients. Support Care Cancer. 2015;23(8):2391-8. doi: https://doi.org/10.1007/s00520-014-2580-x DOI: https://doi.org/10.1007/s00520-014-2580-x
Lupu I, Voiculescu N, Bacalbasa N, et al. Cutaneous complications of molecular targeted therapy used in oncology. J Med Life. 2016;9(1):19-25.
Barton-Burke M, Ciccolini K, Mekas M, et al. Dermatologic reactions to targeted therapy: a focus on epidermal growth factor receptor inhibitors and nursing care. Nurs Clin North Am. 2017;52(1):83-113. doi: https://doi.org/10.1016%2Fj.cnur.2016.11.005 DOI: https://doi.org/10.1016/j.cnur.2016.11.005
Wagner LI, Lacouture ME. Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologis’s perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology (Williston Park). 2007;21(Sup11):34-6.
Boers-Doets CB, Gelderblom H, Lacouture ME, et al. Experiences with the FACT-EGFRI-18 instrument in EGFRI-associated mucocutaneous adverse events. Support Care Cancer. 2013;21(7):1919-26. doi: https://doi.org/10.1007/s00520-013-1752-4 DOI: https://doi.org/10.1007/s00520-013-1752-4
Rosen AC, Case EC, Dusza SW, et al. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. AM J Clin Dermatol. 2013;14:327-33. doi: https://doi.org/10.1007/s40257-013-0021-0 DOI: https://doi.org/10.1007/s40257-013-0021-0
Wagner LI, Berg SR, Gandhi M, et al. The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACTEGFRI-18). Suppot Care Cancer. 2013;21(4):1033-41. doi: https://doi.org/10.1007/s00520-012-1623-4 DOI: https://doi.org/10.1007/s00520-012-1623-4
Boers-Doets CB, Gelderblom H, Lacouture ME, et al. Translation and linguistic validation of the FACTEGFRI- 18 quality of life instrument from English into Dutch. Eur J Oncol Nurs. 2013;17(6):802-7. doi: https://doi.org/10.1016/j.ejon.2013.03.004 DOI: https://doi.org/10.1016/j.ejon.2013.03.004
Bonomi AE, Cella DF, Hahn EA, et al. Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Qual Life Res. 1996;5(3):309-20. doi: https://doi.org/10.1007/bf00433915 DOI: https://doi.org/10.1007/BF00433915
Eremenco SL, Cella D, Arnold BJ. A comprehensive method for the translation and cross-cultural validation of health status questionnaires. Eval Health Prof. 2005;28(2):212-32. doi: https://doi.org/10.1177/0163278705275342 DOI: https://doi.org/10.1177/0163278705275342
Fleiss JL. The design and analysis of clinical experiments. New York: John Wiley & Sons Inc; 1986.
Evans JD. Straightforward statistics for the behavioral sciences. Pacific Grove: Brooks/Cole Publishing; 1996.
SPSS®: Statistical Package for Social Science (SPSS) [Internet]. Versão 23.0. [Nova York]. International Business Machines Corporation. [acesso 2023 mar 9]. Disponível em: https://www.ibm.com/br-pt/spss?utm_content=SRCWW&p1=Search&p4=43700077515785492&p5=p&gclid=CjwKCAjwgZCoBhBnEiwAz35Rwiltb7s14pOSLocnooMOQh9qAL59IHVc9WP4ixhNTVMjenRp3-aEgxoCubsQAvD_BwE&gclsrc=aw.ds
Conselho Nacional de Saúde (BR). Resolução n° 466, de 12 de dezembro de 2012. Aprova as diretrizes e normas regulamentadoras de pesquisas envolvendo seres humanos. Diário Oficial da União, Brasília, DF. 2013 jun 13; Seção I:59.
Clabbers JM, Boers-Doets CB, Gelderblom H, et al. Xerosis and pruritus as major EGFRI associated adverse events. Support Care Cancer. 2016;24:513-21. doi: https://doi.org/10.1007%2Fs00520-015-2781-y DOI: https://doi.org/10.1007/s00520-015-2781-y
Downloads
Published
How to Cite
Issue
Section
License
Os direitos morais e intelectuais dos artigos pertencem aos respectivos autores, que concedem à RBC o direito de publicação.
This work is licensed under a Creative Commons Attribution 4.0 International License.
